Welcome to our dedicated page for ENvue Medical SEC filings (Ticker: FEED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ENvue Medical filings document the public-company reporting, capital structure, governance, and material agreements of a commercial-stage medical device issuer focused on enteral care and guided feeding tube placement. Recent disclosures include a Form 12b-25 notification related to the timing of the company's annual Form 10-K and the review of financial-statement information.
Material-event filings also cover amendments to employment and equity-award arrangements through ENvue Medical Israel, Ltd., a wholly owned subsidiary, and changes to the rights of holders of the company's Series H Convertible Preferred Stock. These records describe certificate-of-designation amendments, preferred-stock terms, securities-holder rights, and related corporate-governance actions.
ENvue Medical, Inc. entered into an Amendment Agreement with required holders of its Series H Convertible Preferred Stock. The parties agreed to amend the existing Certificate of Designations by filing a Certificate of Amendment that removes the defined Floor Price applicable to the Series H preferred.
In return, holders of the Preferred Stock agreed to exercise $2,500,000 of the Additional Investment Right described in the July 18, 2025 Securities Purchase Agreement. The Certificate of Amendment was filed with the Delaware Secretary of State on January 30, 2026 and became effective upon filing, modifying the rights and preferences of the Series H preferred shares.
ENvue Medical, Inc. director Zeev Jhoshua Rotstein filed an initial insider ownership report on Form 3. The filing identifies him as a director of the company and indicates that he does not beneficially own any non-derivative or derivative securities of ENvue Medical. Both ownership tables are blank, and the explanation of responses clearly states that no securities are beneficially owned.